Speed Of Novel Approvals In Jeopardy As RFK Jr. Lands US HHS Secretary Nod

 
• By Sarah Karlin-Smith

The FDA’s Peter Marks warned novel approvals will suffer if the agency is forced to spend its time relitigating vaccines. At the top HHS post Kennedy could impact pharma from basic research funding to drug pricing.

Robert F. Kennedy Jr.
President-elect Trump announced 14 November his intent to nominate RFK Jr. to lead the Health and Human Services Department. (Juli Hansen/Shutterstock.com)

More from US FDA

More from Pathways & Standards